Insulet publishes corporate presentation outlining Omnipod 5 expansion and pipeline roadmap

Insulet Corporation

Insulet Corporation

PODD

0.00
  • Insulet outlined strategy to extend Omnipod leadership in automated insulin delivery, citing 2025 revenue of USD 2.7 billion with more than 600,000 active customers across 25 markets.
  • Roadmap calls for Omnipod 5 ecosystem upgrades in 2026, including algorithm updates with a 100 mg/dL glucose target and broader CGM integration.
  • Omnipod 6 timeline targets clinical study results with 510(k) filing in 2027, followed by launch.
  • Fully closed-loop system for type 2 diabetes targets pivotal study start in 2026, 510(k) filing in 2027, launch in 2028.
  • Penetration targets include U.S. type 1 diabetes rising to 50%-55% by 2028 from about 40%, U.S. type 2 diabetes rising to 10%-15% from about 5%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.